Valuation SOPHiA GENETICS SA Börse Stuttgart
Stocks
90B
CH1125843347
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.450 EUR | 0.00% |
|
+8.43% | +39.18% |
| 08-04 | SOPHiA GENETICS SA, Q2 2026 Earnings Call, Aug 04, 2026 | |
| 08-04 | Sophia Genetics SA and AstraZeneca Enter Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies | CI |
Company Valuation: SOPHiA GENETICS SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 900.4 | 132.3 | 306.8 | 204 | 316.8 | 536.3 | - | - |
| Change | - | -85.31% | 131.92% | -33.51% | 55.34% | 69.26% | - | - |
| Enterprise Value (EV) | 635.1 | -29.03 | 183.5 | 151.6 | 316.8 | 536.3 | 536.3 | 536.3 |
| Change | - | -104.57% | 732.16% | -17.4% | 109.03% | 69.26% | 0% | 0% |
| P/E | -10.6x | -1.51x | -3.86x | -3.23x | -3.99x | -6.8x | -10x | -12.9x |
| PBR | 3.27x | 0.66x | 2.03x | 2.13x | - | - | - | - |
| PEG | - | -0.67x | 0.4x | 0.1x | -0.2x | 0.3x | 0.3x | 0.6x |
| Capitalization / Revenue | 22.3x | 2.78x | 4.92x | 3.13x | 4.1x | 5.65x | 4.58x | 3.63x |
| EV / Revenue | 0x | -0x | 0x | 0x | 0x | 5.65x | 4.58x | 3.63x |
| EV / EBITDA | -0x | 0x | -0x | -0x | -0x | -15.7x | -22x | -33.7x |
| EV / EBIT | -0x | 0x | -0x | -0x | -0x | -8.18x | -11.7x | -14.5x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.33 | -1.36 | -1.22 | -0.95 | -1.17 | -0.926 | -0.628 | -0.49 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 40.45 | 47.56 | 62.37 | 65.17 | 77.27 | 94.92 | 117.1 | 147.9 |
| EBITDA 1 | -67.88 | -82.25 | -66.49 | -57.97 | -41.5 | -34.08 | -24.39 | -15.9 |
| EBIT 1 | -71.49 | -87.82 | -74.83 | -66.57 | -70.91 | -65.56 | -45.86 | -37.07 |
| Net income 1 | -73.68 | -87.45 | -78.98 | -62.49 | -79 | -72.67 | -49.83 | -36.3 |
| Net Debt | -265.3 | -161.3 | -123.3 | -52.39 | - | - | - | - |
| Reference price 2 | 14.100 | 2.060 | 4.710 | 3.070 | 4.670 | 6.300 | 6.300 | 6.300 |
| Nbr of stocks (in thousands) | 63,858 | 64,211 | 65,132 | 66,439 | 67,847 | 85,128 | - | - |
| Announcement Date | 3/15/22 | 3/7/23 | 3/5/24 | 3/4/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.38x | 7.54x | 16.69x | -.--% | 34.68B | |
| 82.54x | 71.2x | 88.7x | 0.42% | 13.28B | |
| 78.69x | 11.59x | 50.31x | 0.74% | 5.44B | |
| -32.54x | 9.61x | -52.05x | - | 2.34B | |
| -6.33x | 63.2x | -6.4x | - | 1.86B | |
| 37.8x | - | - | -.--% | 1.69B | |
| -111.15x | - | - | - | 1.04B | |
| 6.29x | - | - | - | 913M | |
| 123x | - | - | 1.08% | 847M | |
| Average | 23.52x | 32.63x | 19.45x | 0.45% | 6.9B | |
| Weighted average by Cap. | 42.69x | 24.48x | 32.92x | 0.19% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SOPH Stock
- 90B Stock
- Valuation SOPHiA GENETICS SA
Select your edition
All financial news and data tailored to specific country editions
